LabGenomics announced on the 15th that it recorded sales of 14.7 billion KRW in the first quarter. Operating profit and net profit for the same period were 1.1 billion KRW and 4.3 billion KRW, respectively.
As the spread of COVID-19 decreased, the number of PCR (molecular diagnostic) tests significantly declined, causing most diagnostic kit companies to experience poor performance. However, LabGenomics achieved profitability by securing sales channels through diagnostic services and overseas genetic testing.
LabGenomics has established a solid financial structure through stable sales generated from diagnostic services. Based on this, the company plans to actively expand its gene analysis services based on NGS (next-generation sequencing).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
